MX2017008893A - Peptidos antagonistas de prgc. - Google Patents
Peptidos antagonistas de prgc.Info
- Publication number
- MX2017008893A MX2017008893A MX2017008893A MX2017008893A MX2017008893A MX 2017008893 A MX2017008893 A MX 2017008893A MX 2017008893 A MX2017008893 A MX 2017008893A MX 2017008893 A MX2017008893 A MX 2017008893A MX 2017008893 A MX2017008893 A MX 2017008893A
- Authority
- MX
- Mexico
- Prior art keywords
- cgrp antagonist
- antagonist peptides
- formula
- compounds
- peptides
- Prior art date
Links
- 229940127597 CGRP antagonist Drugs 0.000 title 1
- 239000003735 calcitonin gene related peptide receptor antagonist Substances 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/64—Cyclic peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Pyridine Compounds (AREA)
Abstract
La presente invención se relaciona con compuestos de la fórmula (I) o una sal farmacéuticamente aceptable de los mismos: (ver Fórmula) en los cuales m, p, A, Ar1, Ar2, Ar3, R1, R2, y R3 se definen en la descripción. Los compuestos de la fórmula (I) podrán usarse como antagonistas PRGC y podrán usarse para tratar la migraña.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562100371P | 2015-01-06 | 2015-01-06 | |
| PCT/EP2016/050110 WO2016110499A1 (en) | 2015-01-06 | 2016-01-06 | Cgrp antagonist peptides |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2017008893A true MX2017008893A (es) | 2017-10-25 |
| MX387920B MX387920B (es) | 2025-03-19 |
Family
ID=55071041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2017008893A MX387920B (es) | 2015-01-06 | 2016-01-06 | Peptidos antagonistas de prgc. |
Country Status (33)
| Country | Link |
|---|---|
| US (1) | US9969775B2 (es) |
| EP (1) | EP3242882B1 (es) |
| JP (1) | JP6929227B2 (es) |
| KR (1) | KR102713739B1 (es) |
| CN (1) | CN107207567B (es) |
| AR (1) | AR103499A1 (es) |
| AU (1) | AU2016206059B2 (es) |
| BR (1) | BR112017013413A2 (es) |
| CL (1) | CL2017001761A1 (es) |
| CO (1) | CO2017007940A2 (es) |
| DK (1) | DK3242882T3 (es) |
| EA (1) | EA032082B1 (es) |
| ES (1) | ES2924410T3 (es) |
| HR (1) | HRP20220941T1 (es) |
| HU (1) | HUE059379T2 (es) |
| IL (1) | IL252903B (es) |
| JO (1) | JO3669B1 (es) |
| LT (1) | LT3242882T (es) |
| MA (1) | MA41311B1 (es) |
| MD (1) | MD3242882T2 (es) |
| MX (1) | MX387920B (es) |
| MY (1) | MY196439A (es) |
| PH (1) | PH12017501214A1 (es) |
| PL (1) | PL3242882T3 (es) |
| PT (1) | PT3242882T (es) |
| RS (1) | RS63467B1 (es) |
| SA (1) | SA517381865B1 (es) |
| SG (1) | SG11201705306UA (es) |
| SI (1) | SI3242882T1 (es) |
| TN (1) | TN2017000248A1 (es) |
| TW (1) | TWI717331B (es) |
| UA (1) | UA121490C2 (es) |
| WO (1) | WO2016110499A1 (es) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021501784A (ja) * | 2017-11-06 | 2021-01-21 | オークランド ユニサービシーズ リミティド | ペプチド複合体ｃｇｒｐ受容体アンタゴニストおよびその調製方法および使用方法 |
| WO2025202938A1 (en) | 2024-03-26 | 2025-10-02 | Nuvie Bio, Inc. | Pharmaceutical composition comprising a cgrp receptor antagonist for the treatment of acute migraine |
| EP4647082A1 (en) | 2024-05-08 | 2025-11-12 | NUVIE BIO, Inc. | Pharmaceutical composition comprising a cgrp receptor antagonist for the treatment of acute migraine |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6268474B1 (en) * | 1998-04-30 | 2001-07-31 | Creighton University | Peptide antagonists of CGRP-receptor superfamily and methods of use |
| TW200533398A (en) | 2004-03-29 | 2005-10-16 | Bristol Myers Squibb Co | Novel therapeutic agents for the treatment of migraine |
| US20060004185A1 (en) * | 2004-07-01 | 2006-01-05 | Leese Richard A | Peptide antibiotics and peptide intermediates for their prepartion |
| CN101072771B (zh) * | 2004-10-07 | 2010-09-29 | 默沙东公司 | Cgrp受体拮抗剂 |
| SG158191A1 (en) * | 2005-01-17 | 2010-01-29 | Jerini Ag | C5a receptor antagonists |
| AU2006223236A1 (en) * | 2005-03-14 | 2006-09-21 | Merck Sharp & Dohme Corp. | CGRP receptor antagonists |
| US8168592B2 (en) * | 2005-10-21 | 2012-05-01 | Amgen Inc. | CGRP peptide antagonists and conjugates |
| CN101309704B (zh) * | 2005-11-14 | 2012-10-10 | 礼纳特神经系统科学公司 | 针对降钙素基因相关肽的拮抗剂抗体及其使用方法 |
| JP5382799B2 (ja) * | 2006-06-13 | 2014-01-08 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｃｇｒｐ受容体アンタゴニスト |
| AU2013211929B2 (en) * | 2012-01-26 | 2016-05-26 | Christopher J. Soares | Peptide antagonists of the calcitonin CGRP family of peptide hormones and their use |
-
2016
- 2016-01-04 JO JOP/2016/0002A patent/JO3669B1/ar active
- 2016-01-05 TW TW105100158A patent/TWI717331B/zh active
- 2016-01-05 AR ARP160100008A patent/AR103499A1/es active IP Right Grant
- 2016-01-06 DK DK16700059.5T patent/DK3242882T3/da active
- 2016-01-06 PT PT167000595T patent/PT3242882T/pt unknown
- 2016-01-06 MD MDE20170266T patent/MD3242882T2/ro unknown
- 2016-01-06 SI SI201631576T patent/SI3242882T1/sl unknown
- 2016-01-06 AU AU2016206059A patent/AU2016206059B2/en active Active
- 2016-01-06 JP JP2017553460A patent/JP6929227B2/ja active Active
- 2016-01-06 LT LTEPPCT/EP2016/050110T patent/LT3242882T/lt unknown
- 2016-01-06 SG SG11201705306UA patent/SG11201705306UA/en unknown
- 2016-01-06 MY MYPI2017702432A patent/MY196439A/en unknown
- 2016-01-06 CN CN201680005041.7A patent/CN107207567B/zh active Active
- 2016-01-06 EP EP16700059.5A patent/EP3242882B1/en active Active
- 2016-01-06 ES ES16700059T patent/ES2924410T3/es active Active
- 2016-01-06 HR HRP20220941TT patent/HRP20220941T1/hr unknown
- 2016-01-06 TN TN2017000248A patent/TN2017000248A1/en unknown
- 2016-01-06 EA EA201791456A patent/EA032082B1/ru not_active IP Right Cessation
- 2016-01-06 KR KR1020177021133A patent/KR102713739B1/ko active Active
- 2016-01-06 PL PL16700059.5T patent/PL3242882T3/pl unknown
- 2016-01-06 UA UAA201708029A patent/UA121490C2/uk unknown
- 2016-01-06 MX MX2017008893A patent/MX387920B/es unknown
- 2016-01-06 HU HUE16700059A patent/HUE059379T2/hu unknown
- 2016-01-06 WO PCT/EP2016/050110 patent/WO2016110499A1/en not_active Ceased
- 2016-01-06 RS RS20220739A patent/RS63467B1/sr unknown
- 2016-01-06 MA MA41311A patent/MA41311B1/fr unknown
- 2016-01-06 BR BR112017013413-6A patent/BR112017013413A2/pt active Search and Examination
- 2016-01-06 US US15/540,460 patent/US9969775B2/en active Active
-
2017
- 2017-06-14 IL IL252903A patent/IL252903B/en active IP Right Grant
- 2017-06-29 PH PH12017501214A patent/PH12017501214A1/en unknown
- 2017-07-03 CL CL2017001761A patent/CL2017001761A1/es unknown
- 2017-07-04 SA SA517381865A patent/SA517381865B1/ar unknown
- 2017-08-04 CO CONC2017/0007940A patent/CO2017007940A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20025899A (es) | Compuestos útiles para inhibir a cdk7 | |
| EA201792536A1 (ru) | Триазоловые агонисты рецептора apj | |
| EA201891024A1 (ru) | Соединения-ингибиторы tank-связывающей киназы | |
| NI201700020A (es) | Compuestos de aminopirimidinilo como inhibidores de jak | |
| EA201692203A1 (ru) | Соединения, ингибирующие tank-связывающую киназу | |
| EA201792205A1 (ru) | Гетероциклические соединения как ингибиторы lsd1 | |
| EA201892710A1 (ru) | Карбамоилоксиметилтриазолциклогексильные кислоты в качестве антагонистов lpa | |
| EA201591420A1 (ru) | Гетероарильные соединения и их применение | |
| EA201891211A1 (ru) | Ингибиторы cxcr2 | |
| EA201591728A1 (ru) | Гетероциклические соединения и способы их применения | |
| MX377916B (es) | Compuestos 4-amino-imidazoquinolina. | |
| MX2016012097A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cáncer. | |
| EA201691913A1 (ru) | Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов | |
| CO2017011151A2 (es) | Nuevos compuestos bicíclicos como inhibidores de la atx | |
| EA201692526A1 (ru) | Замещенные [1,2,4]триазольные соединения | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| CO2017011152A2 (es) | Nuevos compuestos bicíclicos como inhibidores duales de atx / ca. | |
| MX381487B (es) | Ciertos inhibidores de la proteina quinasa. | |
| EA201690764A1 (ru) | Ингибитор грелин-o-ацилтрансферазы | |
| EA201790327A1 (ru) | Соединения замещенного пиперидина | |
| CL2015002897A1 (es) | Inhibidores de bace1 | |
| JO3793B1 (ar) | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها | |
| EA201500931A1 (ru) | Производные пиридин-4-ила | |
| EA201692289A1 (ru) | Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов | |
| EA201692474A1 (ru) | Производные 1-(циклопент-2-ен-1-ил)-3-(2-гидрокси-3-(арилсульфонил)фенил)мочевины в качестве ингибиторов cxcr2 |